Good news: Irinotecan hydrochloride has once again passed the official audit of Japan's PMDA

2016-04-01

On April 12-14, 2016, Japan's PMDA conducted a 3-day audit of Sichuan Xieli's product Irinotecan Hydrochloride, and the audit results confirmed that Xieli's product met the official Japanese GMP requirements.

2024-11-26

Xieli Pharmaceutical Participates in Pharmtech & Ingredients...

2024-11-18

Sichuan Xieli Pharmaceutical Co., Ltd. 2025 Global Exhibitio...

2024-11-02

Sichuan Xieli Pharmaceutical Co., Ltd. Making a Stunning App...

Composing the International Chapter of the Chinese Pharmaceutical Industry

2024-10-16

Deepening Global Markets: Sichuan Xieli Pharmaceutical Shine...

2024-09-09

Focusing on Global Health, Quality& Innovation Soar Together...

Sichuan Xieli Pharmaceutical Achieves New Heights in Exploring the International Market at CPHI Korea